Compare NTLA & SKYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTLA | SKYT |
|---|---|---|
| Founded | 2014 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2016 | 2021 |
| Metric | NTLA | SKYT |
|---|---|---|
| Price | $12.33 | $30.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 5 |
| Target Price | $20.02 | ★ $26.50 |
| AVG Volume (30 Days) | ★ 4.4M | 1.1M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.43 | ★ 1842.86 |
| EPS | N/A | ★ 2.44 |
| Revenue | $67,671,000.00 | ★ $442,139,000.00 |
| Revenue This Year | N/A | $40.16 |
| Revenue Next Year | $62.75 | $4.52 |
| P/E Ratio | ★ N/A | $12.74 |
| Revenue Growth | 16.92 | ★ 29.18 |
| 52 Week Low | $6.83 | $6.99 |
| 52 Week High | $28.24 | $36.07 |
| Indicator | NTLA | SKYT |
|---|---|---|
| Relative Strength Index (RSI) | 40.61 | 47.37 |
| Support Level | $11.19 | $29.80 |
| Resistance Level | $14.71 | $31.19 |
| Average True Range (ATR) | 1.18 | 1.18 |
| MACD | -0.27 | -0.14 |
| Stochastic Oscillator | 11.03 | 34.42 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
SkyWater Technology Inc is a U.S.-based, independent, pure-play technology foundry that offers semiconductor development and manufacturing services from its fabrication facilities. In its technology as a service model, it leverages a foundation of proprietary technology, engineering to co-develop process technology intellectual property (IP) with its customers that enable disruptive concepts through its Technology Services for diverse microelectronics (integrated circuits) and related micro- and nanotechnology applications. It focuses on serving diversified, high-growth, end users in numerous vertical markets, including computation, aerospace and defense (A&D), automotive and transportation, bio-health, and industrial.